3-氨基-4-甲基-苯甲醛 | 29526-73-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氨基-4-甲基-苯甲醛
• 英文名称: 3-amino-4-methylbenzaldehyde
• CAS: 29526-73-6
• 化学式: C₈H₉NO
• mdl: MFCD11226319
• 分子量: 135.166
• InChiKey: IFRFCGDTWWZZBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2922399090

反应信息

• 作为反应物：
  描述：

  3-氨基-4-甲基-苯甲醛 、 (5Z)-3-acetyl-5-[(pyridin-4-yl)methylidene]-1,3-thiazolidine-2,4-dione 以 乙醇 为溶剂， 生成 (5Z)-3-[(2E)-3-(3-amino-4-methylphenyl)prop-2-enoyl]-5-[(pyridin-4-yl)methylidene]-1,3-thiazolidine-2,4-dione
  参考文献：
  名称：

  Synthesis, Molecular Docking Studies and in vitro and in vivo Hypolipidemic Activity of Thiazolidinedione Derivatives

  摘要：

  This work aimed to design, synthesize novel thiazolidinedione derivatives, which were tested for their antihyperlipidemic effects. Antihyperlipidemic activity was carried through in silico docking study for the 50 thiazolidinedione derivatives (SMI-IV-1 to 50 derivatives) in comparison with standard pioglitazone against the crystal structure of protein PPARgamma (PDB ID: 6QJ5) proteins. Based on the binding energy further, best three derivatives were selected and characterized with IR, NMR and MASS studies. Then, in vitro evaluation of each derivative's antihyperlipidemic activity was carried out by observing their effects on the reduction ability of mature 3T3-L1 adipocyte cells. These cells are susceptible to cytotoxicity because of their internal accumulation of lipids. The vitality of 3T3-L1 adipocytes was identified using the MTT assay. Finally, animal experiments were conducted in order to verify the antihyperlipidemic action of the substance in Wistar rats that had been genetically modified to develop hyperlipidemia. Initially, acute toxicity study was carried out and then based on further study was investigated. Simvastatin (4 mg/kg) was used as standard drug. All the selected three derivatives showed a reversal of the rise in blood triglycerides, cholesterol and LDL from 6 to 48 h and in VLDL from 24 h. All the derivatives showed satisfactory results but derivatives SMI-IV-23 followed by SMI-IV-4 and SMI-IV-31 were given very significant results in terms of binding energy and also in vitro, in vivo experiments. Overall, the results concluded that all the thiazolidinedione derivatives were potent against hyperlipidemic condition and among the all derivatives few derivatives were showed significant role as non-toxic and in mitigation of hyperlipidemia.

  DOI：

  10.14233/ajchem.2024.31107

文献信息

• Modulators of Cellular Adhesion
  申请人：Shen Wang

  公开号：US20110124625A1

  公开（公告）日：2011-05-26

  The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R 1 -R 4 , n, p, A, B, D, E, L and AR 1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).

  本发明提供了具有式(I)的化合物及其药学上可接受的衍生物，其中R1-R4、n、p、A、B、D、E、L和AR1如本文中一般和各类和子类中所述，并且还提供了其药物组成物以及使用它们治疗由CD11/CD18细胞粘附分子（例如LFA-1）介导的疾病的方法。
• ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS
  申请人：Cannizzaro Carina

  公开号：US20090247488A1

  公开（公告）日：2009-10-01

  The invention is related to phosphorus substituted anti-inflammatory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  本发明涉及磷取代的抗炎化合物、含有这种化合物的组合物、包括给药这种化合物的治疗方法，以及用于制备这种化合物的有用过程和中间体。
• PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS
  申请人：Li Xiaolin

  公开号：US20100190811A1

  公开（公告）日：2010-07-29

  The invention provides a novel class of pyrimidine derivatives, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.

  本发明提供了一种新的嘧啶衍生物类，包括这些化合物的药物组合物以及使用这些化合物治疗或预防与异常或非正常激酶活性相关的疾病或疾病的方法，特别是涉及c-kit、PDGFRα和PDGFRβ激酶异常激活的疾病或疾病。
• PROCEDE DE PREPARATION DE COMBRETASTATINE
  申请人：Aventis Pharma S.A.

  公开号：EP2348012A1

  公开（公告）日：2011-07-27

  La présente invention concerne de nouveaux procédés de préparation de combretastatines par condensation de Wittig entre le nitrométhoxy-benzaldéhyde et un sel de phosphonium du triméthoxybenzyle ou à l'inverse un sel de phosphonium du nitrométhoxybenzyle avec le triméthoxybenzaldéhyde.

  本发明涉及通过硝基甲氧基苯甲醛与三甲氧基苄基鏻盐之间的威蒂希缩合，或者反过来，硝基甲氧基苄基鏻盐与三甲氧基苯甲醛之间的威蒂希缩合来制备考布他丁的新工艺。
• Capped diaminopropionamide–glycine dipeptides are inhibitors of CC chemokine receptor 2 (CCR2)
  作者：Percy H. Carter、Gregory D. Brown、Sarah R. Friedrich、Robert J. Cherney、Andrew J. Tebben、Yvonne C. Lo、Gengjie Yang、Heather Jezak、Kimberly A. Solomon、Peggy A. Scherle、Carl P. Decicco

  DOI：10.1016/j.bmcl.2007.07.028

  日期：2007.10

  A new series of CCR2 antagonists has been discovered that incorporates intramolecular hydrogen bonding as a strategy for rigidifying the scaffold. The structure-activity relationship was established through initial systematic modification of substitution pattern and chain length, followed by independent optimization of three different substituents (benzylamine, carboxamide, and benzamide). Several of the acyclic compounds display 10-30 nM binding affinity for CCR2. Moreover, these antagonists are able to block both MCP-1-induced Ca2+ flux and monocyte chemotaxis, and are selective for binding to CCR2 over CCR1 and CCR3. (C) 2007 Elsevier Ltd. All rights reserved.